Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Inc.

Novavax ( ($NVAX) ) has risen by 14.48%. Read on to learn why. Novavax shares climbed 14.48% over the past week as traders and investors responded ...

Novavax Soars as Traders Bet Big on Vaccine Future

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oncolytics Biotech (ONCY – Research Report) and Nova...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released on January 5, from Citi maintained a Sell rating on Novavax, with a price target of $6.00. In a report released yesterday, Ban...

Citi Remains a Sell on Novavax (NVAX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Stereotaxis (STXS – Research Report) and Novavax (NVAX – Research...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVAX	$8.23	-5.29%	2.74M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVAX	$8.23	-5.3%	2.74M
3
4
5
6

NVAX

NVAX

Get Novavax Inc. Data in Excel

Get Novavax Inc. Data in Excel